Company intelligence / Profile preview

Indigo Orb

Irvine, California, United States

Ownership: Private
Development stage: Other

Overview

Indigo Orb was a clinical-stage biotechnology company focused on the development of novel therapies for ocular surface diseases. The company's lead asset, IO-101, is a topical selective glucocorticoid receptor modulator (SGRM) designed to treat dry eye disease. IO-101 was engineered to provide the potent anti-inflammatory benefits of traditional corticosteroids while minimizing the risk of common steroid-induced side effects, such as increased intraocular pressure and cataract formation. In September 2023, Indigo Orb was acquired by Bausch + Lomb to strengthen its comprehensive portfolio of dry eye treatments. The acquisition integrated Indigo Orb's SGRM technology into Bausch + Lomb's established ophthalmology pipeline.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Indigo Orb.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Indigo Orb.

Explore the full profile